Navigation Links
Early Detection Push from New Alzheimer's Disease Discussion Group Points to Advances by Startup Companies, Including Louisville-Based Neuronetrix, Inc.
Date:12/28/2007

LOUISVILLE, Ky., Dec. 28 /PRNewswire/ -- Recent discussions about screening for Alzheimer's disease have begun to stimulate interest in advanced diagnostic technologies. A new advisory group, called AD Screening Discussion Group, has recommended screening for Alzheimer's as patients become eligible for Medicare. The COGNISION(TM) System being developed by Neuronetrix, Inc. is a new Alzheimer's screening technology which will be entering clinical trials in Q1 2008. The COGNISION(TM) System uses proprietary pattern recognition algorithms to classify the patient's brainwave responses based on similarities to known neurological disease profiles. The test is non- invasive, inexpensive, and can be performed in a doctor's office.

Neuronetrix, based in Louisville, KY, will revolutionize the treatment of patients with neurologic disorders by providing meaningful screening information to physicians early in the disease process. Its patent-pending COGNISION(TM) System will "for the first time, directly detect the cognitive deficits associated with Alzheimer's disease," according to K.C. Fadem, inventor of the COGNISION(TM) System.

Alzheimer's is a chronic neurodegenerative disease which afflicts roughly 5 million individuals in the United States. Traditionally, a diagnosis is only made once significant symptoms are present, often 2-4 years into the symptomatic phase of the disease.

"Routine screening is not currently a reality, but it is now appropriate to allow for this, based on the burgeoning senior population in our country and the immense cost to society," according to Dr. Paul R. Solomon, Professor, Department of Psychology and Neuroscience, Williams College; and a member of the AD Screening Discussion Group.

Currently Alzheimer's patients incur direct Medicare/Medicaid costs of more than $50 billion per year, according to the Alzheimer's Association. Mike Reid, CEO of Neuronetrix, indicated that a conservative 5% penetration rate for COGNISION(TM) screening would represent almost $7 billion per year in Americans' cost savings for Alzheimer's care. These savings would be realized by delaying the point at which Alzheimer's sufferers would have to be placed in a long-term care facility. This delay will be due to earlier treatment with current Alzheimer's drugs such as Aricept(R) from Pfizer, Inc. and through treatment with potentially more effective drugs on the near term horizon.

The AD Screening Discussion Group is comprised of a multi-disciplinary panel of experts convened by Eisai Inc., and Pfizer, Inc., to debate the value of screening and early detection for Alzheimer's disease.

For more information, go to http://www.neuronetrix.com.


'/>"/>
SOURCE Neuronetrix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Pot bellies linked to early signs of cardiovascular disease
2. Eye-staining technique offers early detection for dry eye syndrome
3. Early Weight Loss in Women Linked to Dementia
4. Isolation of a new gene family essential for early development
5. U of M study: Early treatment can reverse heart damage
6. Gerresheimer to be Included in the SDAX Early Decision on Inclusion in the MDAX on September 5, 2007
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Pop stars more than twice as likely to die an early death
9. Exercise and yoga improves quality of life in women with early-stage breast cancer
10. Research says doctors gender may hinder early diagnosis of heart disease in women
11. Antidepressant shows early promise in treating agitation and psychotic symptoms of dementia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... ... industry, today announced that it was chosen as the Pharmaceutical News Provider of ... . The awards acknowledge the hard work and dedication of community members who ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Advanced Spine & ... help restore its patients’ health, is hosting a free seminar on stem cell injections. ... held at Advanced Spine & Sport, 4601 Telephone Road, Suite 110, Ventura, CA. There ...
(Date:5/4/2016)... City, Nevada (PRWEB) , ... May 04, 2016 , ... ... bladder infections. Bladder infections, also called UTIs, have plagued people since the beginning ... millions of women get bladder infections every year. It's not just a matter of ...
(Date:5/4/2016)... ... May 04, 2016 , ... With the stamp of approval from the ... May as National Cancer Research Month. According to the American Cancer Society (2016) ... predications of one in four Americans dying as a result. , With numbers as ...
(Date:5/4/2016)... , ... May 04, 2016 , ... Fertility Centers of ... 535 Ocean Ave. Their new Maine Fertility Center provides convenient access to care for ... Rainville and her staff at Women’s Wellness Comprehensive Care in Portland,” said Fertility Centers ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 4, 2016 Research ... "Global Acute Myeloid Leukemia Market and Competitive ... offering.       (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Myeloid Leukemia epidemiology, Acute Myeloid ...
(Date:5/3/2016)... Research and Markets has announced the addition ... Outlook 2020" report to their offering. ... has improved significantly in past years due to which ... years. Many cancer drugs have been developed by utilization ... expected to be developed with its help. They are ...
(Date:5/3/2016)... 3, 2016  While you may be familiar with watching a film or TV show in ... ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: